BG63601B1 - Мезилат трихидратна сол на 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)- индол-2-он (=ципразидон), получаването й и използването й като антагонист на допамин d2 - Google Patents
Мезилат трихидратна сол на 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)- индол-2-он (=ципразидон), получаването й и използването й като антагонист на допамин d2 Download PDFInfo
- Publication number
- BG63601B1 BG63601B1 BG102893A BG10289398A BG63601B1 BG 63601 B1 BG63601 B1 BG 63601B1 BG 102893 A BG102893 A BG 102893A BG 10289398 A BG10289398 A BG 10289398A BG 63601 B1 BG63601 B1 BG 63601B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- mesylate
- ethyl
- benzisothiazol
- piperazinyl
- dihydro
- Prior art date
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title abstract description 28
- 150000003839 salts Chemical class 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 7
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 9
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- LKGCPYOBWLSCTK-UHFFFAOYSA-N methanesulfonic acid;trihydrate Chemical compound O.O.O.CS(O)(=O)=O LKGCPYOBWLSCTK-UHFFFAOYSA-N 0.000 description 24
- 239000013078 crystal Substances 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 239000002552 dosage form Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 229940098779 methanesulfonic acid Drugs 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- -1 2- (4- (1,2-Benzisothiazol-3-yl) -1-piperazinyl) -ethyl Chemical group 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000002441 X-ray diffraction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 150000004684 trihydrates Chemical class 0.000 description 7
- 150000004683 dihydrates Chemical class 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 4
- UAAKJEVCDBPTQS-UHFFFAOYSA-N methanesulfonic acid;dihydrate Chemical compound O.O.CS(O)(=O)=O UAAKJEVCDBPTQS-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UKRXEVNIDNUOLU-UHFFFAOYSA-N 1,3-dihydroindol-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2NC(=O)CC2=C1 UKRXEVNIDNUOLU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 description 2
- QGQMDXQZXNPWDY-UHFFFAOYSA-N 1-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-3h-indol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCN3C(=O)CC4=CC=C(C=C43)Cl)=NSC2=C1 QGQMDXQZXNPWDY-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- JJDARUWULYPFJW-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;methanesulfonic acid;dihydrate Chemical compound O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 JJDARUWULYPFJW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- KVERQKOZMUXLTL-UHFFFAOYSA-N methanesulfonic acid trihydrate Chemical compound O.O.O.CS(O)(=O)=O.CS(O)(=O)=O KVERQKOZMUXLTL-UHFFFAOYSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1653796P | 1996-05-07 | 1996-05-07 | |
| PCT/IB1997/000306 WO1997042190A1 (en) | 1996-05-07 | 1997-03-26 | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG102893A BG102893A (en) | 1999-09-30 |
| BG63601B1 true BG63601B1 (bg) | 2002-06-28 |
Family
ID=21777622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102893A BG63601B1 (bg) | 1996-05-07 | 1998-11-03 | Мезилат трихидратна сол на 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)- индол-2-он (=ципразидон), получаването й и използването й като антагонист на допамин d2 |
Country Status (45)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| ES2204067T3 (es) * | 1998-05-26 | 2004-04-16 | Pfizer Products Inc. | Medicamento para el tratamiento del glaucoma y de la retinopatia isquemica. |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| EA006402B1 (ru) | 1999-12-23 | 2005-12-29 | Пфайзер Продактс Инк. | Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты) |
| HRP20020953A2 (en) * | 2000-06-02 | 2005-02-28 | Pfizer Products Inc. | S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
| UY27668A1 (es) * | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| WO2004050655A1 (en) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride |
| US7488729B2 (en) | 2002-12-04 | 2009-02-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof |
| BRPI0419067A (pt) * | 2003-05-16 | 2007-12-11 | Pfizer Prod Inc | método para aumento da cognição utilizando ziprasidona |
| JP2007522095A (ja) * | 2003-05-16 | 2007-08-09 | ファイザー・プロダクツ・インク | ジプラシドンを用いた不安の治療 |
| BRPI0410378A (pt) * | 2003-05-16 | 2006-06-13 | Pfizer Prod Inc | tratamento de distúrbios psicóticos e depressivos |
| KR20060015750A (ko) * | 2003-06-03 | 2006-02-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법 |
| KR20060115350A (ko) * | 2003-09-02 | 2006-11-08 | 화이자 프로덕츠 인크. | 지프라시돈의 지속 방출형 투여 형태 |
| US7667037B2 (en) * | 2003-10-24 | 2010-02-23 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| JP2007514001A (ja) * | 2003-12-18 | 2007-05-31 | テバ ファーマシューティカル インダストリーズ リミティド | ジプラシドン塩基の多形形態ｂ２ |
| WO2005065660A2 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Ziprasidone formulations |
| EP1720867B1 (en) * | 2004-02-27 | 2009-12-09 | Ranbaxy Laboratories Limited | Process for the preparation of ziprasidone |
| US9044503B2 (en) * | 2004-08-27 | 2015-06-02 | University Of Kentucky Research Foundation | Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally |
| ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
| US7777037B2 (en) * | 2004-10-27 | 2010-08-17 | Dr. Reddy's Laboratories Limited | Ziprasidone process |
| EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| US20070032511A1 (en) * | 2005-02-11 | 2007-02-08 | Judith Aronhime | Amorphous ziprasidone mesylate |
| JP2008531721A (ja) * | 2005-03-03 | 2008-08-14 | エラン・ファルマ・インターナショナル・リミテッド | 複素環式アミド誘導体のナノ粒子状組成物 |
| ITMI20050346A1 (it) | 2005-03-07 | 2006-09-08 | Dipharma Spa | Forma solida di ziprasidone cloridrato |
| US20060270684A1 (en) * | 2005-03-14 | 2006-11-30 | Judith Aronhime | Crystalline forms of ziprasidone mesylate |
| US20060270685A1 (en) * | 2005-03-14 | 2006-11-30 | Judith Aronhime | Anhydrous ziprasidone mesylate and a process for its preparation |
| MX2009011681A (es) * | 2007-05-18 | 2009-11-10 | Scidose Llc | Formulaciones de ziprasidona. |
| KR100948126B1 (ko) * | 2007-12-10 | 2010-03-18 | 씨제이제일제당 (주) | 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물 |
| CN102234273B (zh) * | 2010-04-21 | 2015-08-05 | 上海医药工业研究院 | 甲磺酸齐拉西酮半水合物及其制备方法 |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
-
1997
- 1997-03-26 AU AU19368/97A patent/AU730856C/en not_active Expired
- 1997-03-26 PL PL97329880A patent/PL188164B1/pl unknown
- 1997-03-26 CN CN97194243A patent/CN1092658C/zh not_active Expired - Lifetime
- 1997-03-26 IL IL12659097A patent/IL126590A/en not_active IP Right Cessation
- 1997-03-26 WO PCT/IB1997/000306 patent/WO1997042190A1/en not_active Ceased
- 1997-03-26 TR TR1998/02241T patent/TR199802241T2/xx unknown
- 1997-03-26 DK DK97907237T patent/DK0904273T3/da active
- 1997-03-26 SI SI9730526T patent/SI0904273T1/xx unknown
- 1997-03-26 UA UA98105559A patent/UA47467C2/uk unknown
- 1997-03-26 ES ES97907237T patent/ES2192264T3/es not_active Expired - Lifetime
- 1997-03-26 SK SK1505-98A patent/SK282674B6/sk not_active IP Right Cessation
- 1997-03-26 DE DE69720719T patent/DE69720719T2/de not_active Expired - Lifetime
- 1997-03-26 JP JP09539668A patent/JP3102896B2/ja not_active Expired - Lifetime
- 1997-03-26 HU HU9902808A patent/HU229057B1/hu unknown
- 1997-03-26 EA EA199800909A patent/EA001180B1/ru not_active IP Right Cessation
- 1997-03-26 NZ NZ508303A patent/NZ508303A/en not_active IP Right Cessation
- 1997-03-26 CZ CZ19983494A patent/CZ289216B6/cs not_active IP Right Cessation
- 1997-03-26 US US09/180,456 patent/US6110918A/en not_active Expired - Lifetime
- 1997-03-26 EP EP97907237A patent/EP0904273B1/en not_active Expired - Lifetime
- 1997-03-26 CA CA002252895A patent/CA2252895C/en not_active Expired - Lifetime
- 1997-03-26 AT AT97907237T patent/ATE236902T1/de active
- 1997-03-26 KR KR1019980708958A patent/KR100333214B1/ko not_active Expired - Lifetime
- 1997-03-26 NZ NZ332219A patent/NZ332219A/en not_active IP Right Cessation
- 1997-03-26 PT PT97907237T patent/PT904273E/pt unknown
- 1997-03-26 BR BR9708932A patent/BR9708932A/pt not_active IP Right Cessation
- 1997-04-01 TW TW086104175A patent/TW427989B/zh not_active IP Right Cessation
- 1997-04-02 HN HN1997000040A patent/HN1997000040A/es unknown
- 1997-04-10 GT GT199700042A patent/GT199700042A/es unknown
- 1997-04-28 CO CO97022512A patent/CO4940465A1/es unknown
- 1997-04-30 AP APAP/P/1997/000978A patent/AP838A/en active
- 1997-05-04 EG EG37797A patent/EG24401A/xx active
- 1997-05-05 ID IDP971490A patent/ID17504A/id unknown
- 1997-05-05 AR ARP970101855A patent/AR007003A1/es unknown
- 1997-05-06 MA MA24594A patent/MA26427A1/fr unknown
- 1997-05-06 UY UY24543A patent/UY24543A1/es not_active IP Right Cessation
- 1997-05-06 ME MEP-1997-173A patent/ME00901B/me unknown
- 1997-05-06 MY MYPI97001988A patent/MY128051A/en unknown
- 1997-05-06 YU YU17397A patent/YU49398B/sh unknown
- 1997-05-06 TN TNTNSN97073A patent/TNSN97073A1/fr unknown
- 1997-05-06 DZ DZ970068A patent/DZ2221A1/fr active
- 1997-05-06 ZA ZA973875A patent/ZA973875B/xx unknown
- 1997-05-07 HR HR970235A patent/HRP970235B1/xx not_active IP Right Cessation
-
1998
- 1998-10-23 IS IS4878A patent/IS2301B/is unknown
- 1998-10-30 OA OA9800205A patent/OA10908A/fr unknown
- 1998-11-03 BG BG102893A patent/BG63601B1/bg unknown
- 1998-11-06 NO NO19985193A patent/NO312513B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG63601B1 (bg) | Мезилат трихидратна сол на 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)- индол-2-он (=ципразидон), получаването й и използването й като антагонист на допамин d2 | |
| BG63544B1 (bg) | Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2 | |
| IL175512A (en) | A pure crystalline form of aripiprazole | |
| CN112513026B (zh) | Lta4h抑制剂的晶型 | |
| HK1017893B (en) | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist | |
| MXPA98009242A (en) | Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2- | |
| HUP9902404A2 (hu) | 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(2H)-indol-2-on (ziprazidon) mezilát-dihidrát sói, a vegyületek előállitása és dopamin D2 antagonistaként történő alkalmazása |